Bausch Health registers Phase 2b plecanatide trial in pediatric functional constipation

Bausch Health had one new pediatric trial registration during the week of July 23, 2026.

• Bausch Health Americas, Inc. is sponsoring NCT07723924, a Phase 2b trial of plecanatide (brand name Trulance) in participants age 6 to less than 18 years with functional constipation. The study is designed to learn if plecanatide can treat functional constipation in children and adolescents aged 6 to less than 18 years¹, and is listed as recruiting. The trial plans to enroll approximately 180 participants at up to 30 investigational sites in the United States, randomized in a 1:1:1 ratio to receive low-dose plecanatide, high-dose plecanatide, or matching placebo.¹ The primary efficacy variable is the change from baseline in spontaneous bowel movement (SBM) frequency at Week 8.¹